7 articles
Brown-Forman missed Q1 sales estimates due to weak consumer spending and health trends like GLP-1 drug usage, though it beat EPS and maintained flat annual growth forecasts.
Brown-Forman beat Q4 sales estimates on strong premium spirit demand but forecast flat 2027 growth, citing challenging macroeconomic conditions and cost cycles in the beverage alcohol sector.
Brown-Forman has rejected a roughly $15 billion takeover offer from rival spirits maker Sazerac, according to a Wall Street Journal report citing sources familiar with the matter.
Brown-Forman shares fell 6% after merger talks with Pernod Ricard collapsed due to unmet terms, shifting investor focus to demand challenges and potential Sazerac bids.
Pernod Ricard confirmed the termination of merger negotiations with Brown-Forman, citing failed terms, while rival Sazerac remains a potential bidder.
Pernod Ricard's finance chief confirmed ongoing merger talks with U.S. rival Brown-Forman, while a competing $15 billion offer from Sazerac complicates the potential deal.
Sazerac has made a $15 billion offer to acquire Brown-Forman at $32 per share, challenging Pernod Ricard's merger attempt amid industry-wide sales and cost challenges.
ChemBrief